Dataset from A Phase I Study: Safety of RG2077 (CTLA4-IgG4m) in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune disorder. In this disease, the body's immune system attacks and destroys the cells that cover and protect nerves. This study will test the safety of a new drug called RG2077 that is designed to treat MS. The study will not determine whether RG2077 is effective in treating MS, only whether it is safe to use in patients with MS. Study hypothesis: RG2077 will arrest MS if administered early in the course of MS and decrease accumulation of lesions on MRI.

多发性硬化症（Multiple sclerosis, MS）是一种自身免疫性疾病。该疾病中，机体免疫系统会攻击并破坏包裹、保护神经的细胞。本研究将对一款专为治疗多发性硬化症研发的新型药物RG2077的安全性进行评估。本研究不会探究RG2077治疗多发性硬化症的有效性，仅验证其用于多发性硬化症患者的安全性。本研究的假说为：若在多发性硬化症病程早期给予RG2077，将遏制疾病进展，并减少磁共振成像（MRI）下病灶的累积。